Browse > Article

Hormonal Analysis of Female Transgender Patients Performed Gender Reassignment Operation  

Park, Jung Min (Department of Plastic & Reconstructive Surgery, College of Medicine, Dong-A University)
Kwon, Yong Seok (Department of Plastic & Reconstructive Surgery, College of Medicine, Dong-A University)
Lee, Keun Cheol (Department of Plastic & Reconstructive Surgery, College of Medicine, Dong-A University)
Kim, Seok Kwun (Department of Plastic & Reconstructive Surgery, College of Medicine, Dong-A University)
Kwak, Hyun (Department of Physical Medicine and Rehabilitation, College of Medicine, Dong-A University)
Kim, Sang Beom (Department of Physical Medicine and Rehabilitation, College of Medicine, Dong-A University)
Publication Information
Archives of Plastic Surgery / v.32, no.6, 2005 , pp. 699-705 More about this Journal
Abstract
Transgender is the severe type of gender identity disorder. The prevalence rate of transgender is reported to occur to about 1 out of 50,000 men, and about 1 out of 10,000 women. As for Korea, it is estimated to have about 1400 transgender patients. Lately, not only the numbers of them are increasing but also they are influencing our society increasingly. As for female transgender patients, they take female hormone for a long term before and even after the operation to maintain their physical identity of female. We have analyzed insulin like growth factor-1(IGF-1), insulin like growth factor protein binding-3(IGFBP-3), female hormone, male hormone and thyroid hormone in female transgender patients who have undergone the gender reassignment operation. We examined the changes of hormone level due to having female hormone steadily, and also examined how the steady use of the hormone could affect body organs. As for IGF-1, it showed significantly low in the female transgender group compared to control ($319.30{\pm}37.4$ vs $539{\pm}55.0$, p<0.05). As for IGFBP-3, there was no significant difference ($2859{\pm}200.3$ vs $2607{\pm}262.5$, p>0.05). As for female hormone, there was no significant differences in FSH($13.42{\pm}13.8$ vs $8.95{\pm}3.5$, p>0.05), estradiol($104.41{\pm}97.1$ vs $121.68{\pm}60.2$, p>0.05), and LH($7.62{\pm}5.6$ vs $7.4{\pm}3.3$, p>0.05). Even in comparison of testosterone, there was no significant differences($0.23{\pm}0.09$ vs $0.33{\pm}1.33$, p>0.05). As for thyroid hormone, there was no significant differences in TSH and free T4($1.34{\pm}0.94$ vs $1.71{\pm}0.12$, $1.4{\pm}0.37$ vs $1.46{\pm}0.17$, p>0.05). Therefore, this study concludes that apart from the decreased level of IGF-1, the possible endocrine side-effect problem due to female hormone seems to be low because there was no differences of female, male, and thyroid hormone level compared with normal female. Further study will be required in metabolic change including bone metabolism occurred by decrease level of IGF-I.
Keywords
Female transgender patients; Hormone;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Walter JM, Mayer III WJ, Webb A, Stnart LA, Finkelstein JW, Lawrence B, Walker PA, Alice W, Charles AS, Jordan WF, Barbara L. Paul AW: Physical and hormonal evaluation of transsexual patients; A longitudinal study. Arch of Sexual Behavior 15: 121, 1986   DOI   ScienceOn
2 Kesteren P, Lips P, Deville W, Popp-snijders C, Asscheman H, Megens J, Gooren L: The effect of one-year corss-sex hormonal treatment on bone metabolism and serum insulin-like growth facter-1 in transsexuals. J Clin Endocrinol Metab 81: 2227, 1996   DOI   ScienceOn
3 Schmidt G: Hepatocelluar carcinoma; A possible complication of oral contraceptive steroids. Med J Australia 1: 215, 1977
4 Park JM, Ok YC, Son HS, Jung GW, Kim SK: Anatomic and Histologic changes of the testis after long-term estrogen exposure in transsexuals. Kor J Androl 18: 117, 2000
5 Gunasegaram R, Loganath A, Peh KL, Rantham SS: Aromatization of [4-$^{14}C$] testosterone to [$^{14}C$]estradiol -17 $\beta$ by testicular tissue from male-to-female transsexuals of estrogen therapy. Arch Androl 35: 127, 1995   DOI
6 Lips P, Asscheman H, Uitewaal P, Netelenbos JC, Gooren L: The effect of cross-gender hormonal treatment on bone metabolism in male-to-female transsexuals. J Bone Mine Res 4: 657, 1989
7 Sorva R, Dunkel KL, Taskinen MR: Effect of endogenous sex steroids on serum lipoproteins and postheparin plasma lipolytic enzymes. J Clin Endocrinol Metab 68: 408, 1988
8 Kim JH, Park SH, Park JM, Kim SK: Anatomic and histologic changes of the penis after long-term estrogen therapy in transsexuals. J Korean Soc Plast Reconstr Surg 25: 1284, 1998
9 Ganong WF: Review of medical pathophysiology. 18th ed, Seoul, Hanwoori, 2002, p 433
10 Stefanick ML, Williams PT, Krauss RM, Terry RB, Vranizan KM, Wood PD: Relationships of plasma estradiol, testosterone, and sex hormone-binding globulin with lipoproteins, apolipoproteins, and high-density lipoprotein subfractions in men. J Clin Endocrinol Metab 64: 723, 1987   DOI
11 Lubbert H, Leo-Ro B berg I, Hammersein J: Effect of ethinyl estradiol on semen quality and various hormonal parameters in a eugonadal male. Fertil Steril 58: 603, 1992
12 Ganong WF: Review of medical pathophysiology. 18th ed, Seoul, Hanwoori, 2002, p 472